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BAD guideline for management of Bowen 
disease, 2014
Morton et al. state that the overall objective of this guideline is 
to provide up-to-date, evidence-based recommendations for the 
management of squamous cell carcinoma in situ (Bowen dis-
ease). The document updates and expands the previous British 
Association of Dermatologists’ guideline on this topic as fol-
lows: offering an appraisal of all relevant literature since January 
2006; focusing on any key developments; addressing important, 
practical clinical questions relating to the primary guideline 
objective; providing guideline recommendations and, where 
appropriate, some health economic considerations; discussing 
potential developments and future directions. The guideline is 
presented as a detailed review with highlighted recommenda-
tions for practical use by clinicians in the clinic. The guideline 
also reviews penile intraepithelial neoplasia and bowenoid pap-
ulosis, which have similar histology and are often diagnosed by 
dermatologists; however, the authors emphasize that a detailed 
therapeutic review of these conditions is beyond the scope of 
this guideline. Br J Dermatol 2014; 170: 245–260.
The impact of cutaneous lupus damage on 
quality of life 
Verma et al. state that patients with more severe cutaneous 
lupus erythematosus (CLE) have a poorer quality of life (QoL). 
They go on to explain that racial and ethnic disparities have 
been reported in disease activity and outcomes in systemic 
lupus erythematosus, but similar information is not available 
for CLE. The aims of this study were to evaluate the impact 
of lupus-related skin damage on skin-specific QoL, and to 
analyse differences stratified by ethnic background. Overall, 
223 patients were analysed at baseline, with 141 completing 
more than one study visit. Data collected included sex, race, 
diagnosis and CLE Disease Area and Severity Index (CLASI) 
and Skindex-29 scores. These parameters were analysed at 
the initial and last visits. CLASI damage scores (dyspigmenta-
tion and scarring) and activity scores were collected, grouped 
by ethnicity, and correlated with Skindex-29. There was no 
significant correlation between CLASI damage scores and 
Skindex domains overall. Individually, dyspigmentation and 
scarring also did not have a significant effect on QoL. Ethnic 
differences in patients with CLE were found: African American 
patients exhibited a high rate of DLE and experienced damage 
early in their disease course, frequently in conjunction with 
disease activity. African American patients with cutane-
ous lupus present initially with greater disease damage than 
white patients, and in conjunction with disease activity. It is 
disease activity, as measured by CLASI, and not damage or its 
parameters of scarring and dyspigmentation, that aff ect QoL. 
Dyspigmentation in cutaneous lupus does not appear to have 
the same effect that other diseases of dyspigmentation have on 
QoL. Br J Dermatol 2014; 170: 315–321.
Incidence rates of malignancies and infections 
in psoriasis
Kimball et al. open this paper by highlighting that the limited 
data available suggest higher rates of malignancies and hospi-
talized infectious events (HIEs) among patients with psoriasis; 
it is unclear whether the higher rates are associated with the 
underlying inflammatory state, treatments, or both. Their stated 
aim was to assess the incidence of malignancies and HIEs in 
a healthy US population, a psoriasis population, and four 
treated psoriasis populations. A US administrative claims data-
base was used to identify a healthy population and a psoriasis 
cohort to assess the incidence of lymphomas, nonmelanoma 
skin cancer (NMSC), all malignancies (excluding NMSC) and 
HIEs. Age- and sex-standardized incidence rates and 95% con-
fidence limits were calculated. This study showed that patients 
with psoriasis appear to have higher rates of malignancy and 
HIEs than the general population, with little difference in rates 
between the treatment methods. The authors concluded that 
the elevated rates of malignancy and serious infections found 
in patients with psoriasis in this study may be due to other bio-
logical reasons rather than specific treatment modalities. Br J 
Dermatol 2014; 170: 366–373.
Efficacy and safety of systemic treatments for 
moderate-to-severe psoriasis
Schmitt et al. carried out a meta-analysis of randomized con-
trolled trials of systemic treatments for moderate-to-severe 
psoriasis. Their aim was to analyse systematically the efficacy 
and safety of approved treatments. Efficacy was defined as 
the proportion of participants with a 75% improvement in 
Psoriasis Area and Severity Index at the primary efficacy mea-
surement (week 8–16). Safety, in the context of these studies, 
was summarized as rates of adverse events and withdrawals. 
The authors identified 48 eligible RCTs with a total of 16,696 
patients (11,178 randomized to biologics, 1,888 to convention-
al treatments). Safety of treatments could not be pooled due to 
a lack of standardization in reporting across trials. The authors 
concluded that qualitative and quantitative evidence is much 
stronger for biological interventions than for conventional treat-
ments. Br J Dermatol 2014; 170: 274–304.
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